Objective. To elucidate changes in endothelial function throughout the gestational period in 2 normal pregnancy and its relationship with plasma sFlt-1 levels. Methods. Endothelial 3 function was evaluated by reactive hyperemia index (RHI) using Endo-PAT2000 and plasma 4 sFlt-1 levels were measured simultaneously by ELISA. Results. RHI gradually deteriorated 5 with increasing the gestational age. Plasma sFlt-1 levels exhibited a gradual increase at late 6 pregnancy and were inversely correlated with RHI. Conclusion. Maternal endothelial function 7 gradually deteriorates with increasing gestational age and there is an inverse correlation 8 between endothelial function and plasma sFlt-1 levels in normal pregnancy. 9 10
INTRODUCTION

1
In normal pregnancy, blood volume and cardiac output increase as pregnancy proceeds. By 2 contrast, blood pressure gradually decreases slightly toward mid-pregnancy and then slowly 3 increases toward the term (1). It is assumed that this discrepancy is due at least in part to 4 alterations in endothelial function based on reductions in systemic vascular resistance by 5 nitric oxide (NO) (2) . In preeclampsia (PE), it is acknowledged that poor placentation in early 6 pregnancy causes placental hypoperfusion with subsequent maternal endothelial dysfunction. 7
The endothelial dysfunction in various tissues is implicated in symptoms such as hypertension, 8 proteinuria, tissue oedema, cerebral haemorrhage, and so on (3). Therefore an assessment of 9 endothelial function might be useful for prediction, prevention, and curative strategies for PE 10 patients. However, it is still controversial whether endothelial function changes throughout 11 normal pregnancy (4-8). 12
Endothelial function includes vasodilatory, anti-coagulant, anti-inflammatory and 13 vascular permeability activities. It is thought that vascular homeostasis is well maintained (9) 14 and NO and vascular endothelial growth factor (VEGF) play central roles in these 15 mechanisms. Soluble fms-like tyrosine kinase-1 (sFlt-1) has been implicated in the symptoms 16 of PE. It is a soluble type of VEGFR-1 and competes with VEGF for binding to VEGF 17 receptors. Rats over-expressing sFlt-1 show similar clinical features of PE (10). In PE patients, 18
increased circulating sFlt-1 levels have been reported compared with normal pregnant womendependent endothelial function (17). In addition, Aragones reported that elevated levels of sE-1 selectin, a biomarker for endothelial dysfunction, were associated with lower RHI (18). 2 However there have been few articles so far investigating the role of endothelial function 3 using RHI in PE patients. One report presented reduced RHI in patients with PE compared 4 with normal pregnant women around 32 weeks of gestation (19). Recently, Carty et al. 5 demonstrated that RHI in pregnant women at 28 weeks was significantly lower than that at 16 6 weeks (14), but they just focused on the predictive value of the onset of PE and concluded 7 that it failed for that purpose. 8
Here we report a prospective study of monitoring maternal RHI to evaluate endothelial 9 function throughout the normal gestational period using the Endo-PAT system. We also 10 measured endothelial function and circulating sFlt-1 levels in non-pregnant women, 11 preeclamptic patients and pregnant women who develop PE later. Because the significance of 12 increased sFlt-1 levels in normal late gestation has not been clarified, we measured plasma 13 sFlt-1 levels in all subjects and evaluated the relationship between RHI and plasma sFlt-1 14 levels. The aim of this study was to elucidate alterations in endothelial function using the PAT 15 system and its correlation to plasma sFlt-1 levels throughout the normal gestational period as 16 well as the process of PE. 17
MATERIALS AND METHODS
controlled (23 to 26 ℃), quiet and dark room was reserved for the examination. A blood 1 pressure cuff was placed on one upper arm and a probe was placed on the tip of the index 2 finger; the probe sensor on the contralateral arm served as a control. Following approximately 3 15 min of resting in a supine position on the bed, the baseline digital volume signals were 4 recorded for 5 min, then the blood pressure cuff was inflated to 200 mmHg to occlude the 5 brachial artery and the pressure was maintained for 5 min. The cuff was then released to 6 induce RH and the reaction was recorded for 5 min. The analytical method of calculating RHI 7 was as follows. The RHI reflects the ratio of the alteration in the amplitude from 90 to 150 8 seconds after the cuff is released (occluded arm -A; non-occluded arm -C) divided by the 9 average amplitude of the signal from 170 to 20 seconds before the cuff is inflated (occluded 10 arm -B; non-occluded arm -D). This value was calculated using the formula: RHI = (A/B) / 11 (C/D). The RHI data were digitally analysed using the Endo-PAT2000 software version 3.3.2 12 (Itamar Medical). Each pregnant woman underwent this test 1 to 3 times at intervals of longer 13 than one month apart. 14 15 Plasma Sampling and Measurement of sFlt-1 Levelscentrifugation at 3000 rpm for 30 min. The supernatants were stored at -20 ℃ until analysis. 1 Plasma sFlt-1 levels were measured using a human sVEGFR1/Flt-1 enzyme-linked 2 immunosorbent assay (ELISA) kit (R&D Systems, Minneapolis, MN) in duplicate according 3 to the manufacturer's protocol. Inter-assay and intra-assay coefficients of variation were 5.5-4 9.8 % and 2.6-3.8 %, respectively. 5 6 Diagnosis of PE 7 PE was defined as the new onset of hypertension and proteinuria after 20 weeks of 8 gestation. Hypertension was defined as a systolic blood pressure ≥ 140 mmHg or diastolic 9 blood pressure ≥ 90 mmHg on two measurements at least 4 hours apart, and proteinuria as ≥ 10 300 mg/day (21). In Japan, it is defined that late-onset preeclampsia develops at or after 32 11 weeks of gestation. 12
13
Statistical Analysis 14
The results of normally distributed continuous variables are expressed as the mean ± 15 SEM (range), while those with skewed distribution are expressed as the median value with 16
[interquartile range]. Continuous variables were analysed by the Wilcoxon t test, MannStatistical analyses were performed using Prism 3.0 (GraphPad Software, La Jolla, CA). 1 2
RESULTS
3
Patient Characteristics 4
The information collected on the study population is shown in Table 1 . Three of 29 5 pregnant women developed PE. Body mass indexes were significantly higher in the normal 6 control pregnant women than in the non-pregnant women. In 7 PE patients, systolic and 7 diastolic blood pressures were not high due to antihypertensive treatment and the median time 8 of measuring RHI was 32 [31.5-34] weeks of gestation. The average of systolic blood 9 pressure was 161 ± 5 mmHg, and the diastolic blood pressure was 95 ± 4 mmHg, when PE 10 patients were diagnosed at first time. RHI measurements in PE patients were performed 4 11 [2.5-5.5] days after start of the treatment. Gestational age at delivery was earlier in the PE 12 group than in normal pregnant women. Neonatal weight was also lighter in the PE patients 13 than in normal pregnant women and patients with late PE development. 14 15 were given repeat measurements in each gestational period. The RHI in pregnant women over 10 32 weeks of gestation was significantly lower than in those under 19 weeks of gestation. In 11 contrast, plasma sFlt-1 levels in pregnant women over 32 weeks of gestation were 12 significantly higher than those less than 20 weeks or between 20 and 31 weeks of gestation. 13
Alterations of RHI in Normal Pregnancy
14
RHI and Plasma sFlt-1 Levels in PE and Late PE Development Patients 15
The RHI in PE patients was significantly higher than in normal pregnant women at the 16 same gestational stage (31-36 weeks) ( Figure 5A ). On the other hand, plasma sFlt-1 levelsdays after the delivery. In another case, it was similarly increased (1.65 to 1.84) twelve days 1 after the delivery. 2
Three of 29 pregnant women developed PE in this study. The RHI and plasma sFlt-1 3 levels were measured at 10-15 weeks and 29-32 weeks of gestation, before the onset of PE in 4 these 3 patients. Both RHI and plasma sFlt-1 levels were no different at 10-15 weeks of 5 gestation. While RHI was still comparable at 29-32 weeks of gestation, plasma sFlt-1 levels 6
were slightly higher in patients with late PE development. significantly lower than at 16 weeks (14). In the present study, we examined endothelial 6 function by PAT in more detail and demonstrated that RHI gradually decreases with 7 increasing gestational age, consistent with recent reports (14). Therefore we conclude that 8 endothelial function was deteriorating even in normal pregnancy. 9
Although it has been already shown that sFlt-1 levels are increasing during gestation, we 10 first that demonstrated that plasma sFlt-1 levels and RHI were inversely correlated. Until now, 11 there is no study showing a correlation between endothelial function and plasma sFlt-1levels 12 in normal pregnant women. As one of the reasons, we think that data analysis by FMD 13 method may have some difficulty, in terms of convenience, quantitation, and reproducibility. 14 Increased plasma sFlt-1 are suggested to neutralize VEGF and attenuate the beneficial effect 15 of VEGF on endothelial function in PE patients, though the relation between plasma sFlt-1 16 levels and endothelial function remains unclear in normal pregnancy. From the current results, 17 it can be speculated that the elevation of plasma sFlt-1 levels in the late pregnancy may causeendothelial function directly and further studies will be needed to elucidate this relationship. 1
In our findings, the RHI in PE patients was relatively high. Markedly increased plasma 2 sFlt-1 levels in PE patients strongly suggest poorer endothelial function (22). It has already 3 been demonstrated that FMD is reduced in PE patients (23-25). Therefore our results appear 4 curious and must be interpreted with caution. The following two reasons may account for 5 about the cause of dissociation of this result. First, all PE patients in our study were medicated 6 with calcium blocker and/or magnesium sulfate, which potentially improved their endothelial 7 function. Second, there is a report that RH itself is slightly pressure-dependent (β = 0.007, p 8 < 0.001) (26). Generally, it is thought that endothelial dysfunction leads to hypertension and 9 arteriosclerosis. However, in the presence of high blood pressure, an evaluation of endothelial 10 function by PAT may be influenced by blood pressure. In PAT analysis, in contrast to our 11 result showing increased RHI, Yinon et al. (19) have reported decreased RHI in a study in PE 12 patients in which cases of relatively early onset were enrolled more frequently than in ours. It 13 is probable that markedly depressed endothelial function leads to a lower RHI despite the 14 presence of high blood pressure. Thus the relatively high RHI values in PE patients might be 15 due to their higher blood pressure level or to drugs, though this needs to be further elucidated. 16
The limitation to the present study was that the number of patients who developed PE at 17 the later gestational stage was too small for us to be able to assess whether endothelial 18 function in the early stages of gestation is able to predict the onset of PE.
Angiogenic factors, including VEGF, in maternal vessels are important for maintaining 1 normal endothelial function. In PE patients, the normal balance between angiogenesis and 2 anti-angiogenesis has been compromised by circulating factors, including sFlt-1 and others, 3 from the placenta. Up to the present, there is no method to evaluate endothelial function that 4 combines non-invasiveness with convenience, quantitation and reproducibility. Although 5 further study must be done regarding the influence of blood pressure levels, it appears that 6 PAT will become a useful tool to assess maternal endothelial function hereafter. We believe 7 research into predicting or understanding the pathogenesis of PE might progress if more 8 measurements of anti-angiogenic or angiogenic factors in maternal blood can be added to the 9 accumulating data on this topic. 10
In conclusion, we here evaluated maternal endothelial function using the novel 11 methodology of the Endo-PAT2000 system and simultaneously measured plasma sFlt-1 levels 12 in pregnant women. Our investigation revealed that maternal endothelial function gradually 13 deteriorated while plasma sFlt-1 levels increased in inverse correlation with gestational age in 14 normal pregnancy. Anti-angiogenic or angiogenic factor profiling combining with RHI will 15 be valuable for predicting and understanding the pathogenesis of PE. 16 
